Due to its marked efficacy in the prevention of bone loss in susceptible populations, alendronate (generic name of BIS) had been proposed as a useful agent to prevent alveolar bone loss.

Results of this study indicate that, after 2 years of follow up, the oral administration of BIS did not have a protective effect on the mean alveolar bone loss. Although a recent systematic review ...